Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study - Takeaways - MDSpire

Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study

  • By

  • Guangxi Wang

  • Xiaonan Lu

  • Yunmei Wang

  • Xiang Wang

  • Ruoxuan Wang

  • Jinyu Jia

  • June 3, 2026

  • 0 min

Share

  • 1

    Continuing immune checkpoint inhibitors beyond progression (CIBP) significantly improves median progression-free survival compared to non-ICI treatments.

  • 2

    The CIBP group showed a median overall survival of 9.5 months, outperforming the 6.4 months seen in the non-CIBP group.

  • 3

    Subgroup analyses indicated that patients with PD-L1 expression ≥1% benefited most from continuing ICI therapy after progression.

  • 4

    The safety profile of CIBP was manageable and comparable to that of non-ICI regimens in the study population.

  • 5

    CIBP is a promising second-line strategy for selected patients with advanced gastric cancer following first-line immuno-chemotherapy failure.

Original Source(s)

Continuing immune checkpoint inhibitors beyond progression versus switching to non-ICI therapy in advanced gastric cancer: a real-world study

  • by Guangxi Wang, Xiaonan Lu, Yunmei Wang, Xiang Wang, Ruoxuan Wang, Jinyu Jia

  • June 3, 2026

Related Content

Acute changes in sexual function, hormonal profiles, and psychological status following intensity-modulated radiotherapy in male patients with nasopharyngeal carcinoma

Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma

Complete radiographic response to immunotherapy in a patient with metastatic anaplastic thyroid cancer – a case report and review of the literature